Page last updated: 2024-09-05

deferasirox and Melanoma

deferasirox has been researched along with Melanoma in 2 studies

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's2 (100.00)2.80

Authors

AuthorsStudies
Han, X; Song, P; Wang, Y; Wu, X; Yan, J; Zhang, H; Zheng, R1
Mirian, M; Rostami, M; Varshosaz, J; Veisi, H1

Other Studies

2 other study(ies) available for deferasirox and Melanoma

ArticleYear
Upregulation of MHC-I and downregulation of PD-L1 expression by doxorubicin and deferasirox codelivered liposomal nanoparticles for chemoimmunotherapy of melanoma.
    International journal of pharmaceutics, 2022, Aug-25, Volume: 624

    Topics: Animals; B7-H1 Antigen; Cell Line, Tumor; Deferasirox; Down-Regulation; Doxorubicin; Immunotherapy; Liposomes; Major Histocompatibility Complex; Melanoma; Mice; Nanoparticles; Phosphatidylinositol 3-Kinases; Tumor Microenvironment; Up-Regulation

2022
Thermosensitive TMPO-oxidized lignocellulose/cationic agarose hydrogel loaded with deferasirox nanoparticles for photothermal therapy in melanoma.
    International journal of biological macromolecules, 2023, May-31, Volume: 238

    Topics: Deferasirox; Humans; Hydrogels; Iron; Melanoma; Nanoparticles; Nuclear Proteins; Photothermal Therapy; Polymers; Pyrroles; Sepharose; Thymopoietins

2023